Antineoplastic Agents

All Drugs and Chemicals

Sorafenib

Protein Kinase Inhibitors

Enzyme Inhibitors

Eligible patients (not candidates for curative treatment) will have measurable lesions in the anatomic thorax, abdomen or pelvis (any histology) amenable to palliative radiation treatment (30 Gy in 10 fractions). Patients receive sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. If full oral dose (400 mg po bid) is reached in a given cohort (dose level three) then an additional dose level will open where sorafenib treatment (400 mg bid) is extended following radiation for a total of eight weeks.

Sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. Dose level 1 is 200mg of sorafenib. If full oral dose (400mg orally, twice a day) is reached in a given cohort then an additional dose level will open where sorafenib treatment is extended following radiation for a total of eight weeks.

Anthony Brade

The purpose of this study is to test the combination of radiation treatment and an anti-angiogenic drug called sorafenib (or BAY 43-9006 or Nexavar) to determine the effects of this combination on cancers but also on side effects of radiation treatment. This study will also determine the highest safe dose of sorafenib that can be given with radiation treatment.

A Study of Radiation With Sorafenib in Advanced Cancer

A Phase I Dose Escalation Study of Concurrent Low Dose Radiation With Sorafenib in Three Anatomically-based Independent Cohorts (Thorax, Abdomen, Pelvis)

To measure safety and maximum tolerated dose, all adverse events will be assessed in line with dose limiting toxicities.

To assess the efficacy of adding sorafenib to radiation treatment, radiological imaging will be used to assess response rate inline with the RECIST criteria.

University Health Network, Toronto

Neoplasms

All Conditions

Musculoskeletal Diseases

Rare Diseases

Sarcoma

Bone Neoplasms

Bone Diseases

Soft Tissue Sarcoma

Surgical treatment using a patient specific instrument (PSI)

Conventional surgical treatment without PSI, using 2D imaging planification

The proposed innovation consists in using patient specific instrument (PSI) for tumor resection. It is compounded of a preoperative assistance to plan the surgery and an intraoperative assistance to reproduce the preoperative planning.

Patient specific instrument

The conventional treatment is planned on two-dimensional images (CT and MRI).

Conventional surgical treatment

François Gouin, Professor

Primitive malignant bone tumor or mixt tumor (compounded of soft tissues and bone) is a rare pathology particularly within the pelvis, the sacrum or the hip (between 25 and 80 new cases in France per year).

The reference treatment is a surgical "en bloc" resection associated or not to a medical treatment. This surgery remains highly challenging because of the complex three-dimensional geometry of the pelvic bone and the proximity of important organs and neurovascular structures. The local recurrence rate is significantly increased when the resection does not respect a safe tissues margin (R0 margin).

A new technology has been developed and used in different reference sites the Patient Specific Instrument (PSI), manufactured by 3D-Side. The PSI allows for a more secure and reliable surgical gesture, leading to more frequent R0 margins.

The main objective of this study is to compare the efficiency of the PSI for bone tumor resections within the pelvis with respect to the reference method.

Cost-effectiveness Evaluation of the Use of a Patient Specific Instrument for Surgical Resection of Malignant Bone Tumor Within the Pelvis Versus the Conventional Surgical Treatment

Incremental Cost-Effectiveness Ratio (ICER) as assessed from the healthcare system perspective: Cost/Local prevented recurrence at 3 years postoperatively

R0, R1 and R2 margin rates as observed by histological exam for each surgical treatment, for each treatment group.

QALYs measures for this group will be extrapolated from the prospective group by estimating the impact of a local recurrence on health-related quality of life.

Musculoskeletal Tumor Society (MSTS) Score which evaluates 6 items: pain, function, emotional acceptance, walking capacity, technical walking aids, gait.

Toronto Extremity Salvage Score (TESS) which evaluates 30 items about the global function and patient's activity level.

Nantes University Hospital

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Carcinoma

Urinary Bladder Neoplasms

Carcinoma, Transitional Cell

Urinary Bladder Diseases

Ureteral Diseases

Ureteral Neoplasms

Pelvic Neoplasms

Urethral Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urologic Diseases

Male Urogenital Diseases

Urethral Diseases

Transitional Cell Carcinoma

Urethral Cancer

Gemcitabine

Cisplatin

Antimetabolites

Dose Escalation: Begin with Level 1 dose of enzalutamide (orally), with standard doses of cisplatin and gemcitabine via intravenous (IV).

Dose Expansion: Enzalutamide at recommended dose level with standard doses of cisplatin and gemcitabine.

Enzalutamide orally once a day. Dose Escalation Level 1: 80 mg; Level 2: 160 mg. Dose Expansion at recommended dose level, after dose escalation.

Enzalutamide

Cisplatin at 70 mg/m\^2 IV on day 1, repeated every 21 days for total of 6 cycles.

Gemcitabine at 1000 mg/m\^2 IV on days 1, 8, repeated every 21 days for total of 6 cycles.

Jingsong Zhang, M.D., Ph.D.

Shilpa Gupta, M.D.

The main purpose of this study is to find out the dose of enzalutamide that can be safely given with gemcitabine and cisplatin in patients with advanced bladder cancer. Researchers also want to find out the side effects of these drugs when given together. This study will also help in finding out the effect on tumor of the combination of enzalutamide, gemcitabine and cisplatin.

For the phase 1 dose escalation phase, the starting dose of enzalutamide will be 80 mg orally once a day (Level 1). The dosing regimen of cisplatin and gemcitabine will be at standard doses of Gemcitabine at 1000 mg/m\^2 IV on days 1, 8 and cisplatin at 70 mg/m2 IV on day 1, repeated every 21 days for total of 6 cycles.

Three patients will be treated dose level 1 (enzalutamide 80 mg daily). If 0 patients experience dose limiting toxicity (DLT), dose escalation will be done to level 2 of enzalutamide 160 mg daily. If 1 patient experiences DLT, 3 more patients will be treated at the same dose level; if 1 of 6 experiences DLT, escalate the dose to next level, and if 2 or more of 6 experiences DLT, the dose level 1 (80 mg enzalutamide) will be the recommended dose for dose expansion cohort.

The cohort expansion will then be done by enrolling 12 patients with stage IV bladder cancer, who express androgen receptor (AR) staining of 1+ and above by immunohistochemistry (IHC), to determine the safety and tolerability of cisplatin and gemcitabine with the recommended dose level of enzalutamide (80 mg or 160 mg, depending upon the safety results from dose escalation part) in this expanded cohort of patients with AR + bladder cancer.

Enzalutamide would be continued after completion of 6 cycles of gemcitabine-cisplatin for patients exhibiting a response or stable disease, until they experience disease progression.

Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer

A Phase I/1b Study of Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer

Dose Escalation. Maximum Tolerated Dose (MTD) of Enzalutamide when given with Cisplatin and Gemcitabine at standard doses. Dose Level 1: 80 mg Enzalutamide; Dose Level 2: 160 mg Enzalutamide.

Dose-Limiting Toxicity (DLT) is defined as any of the following occurring in the first 21 days (cycle 1) of study participation that are considered at least possibly related to enzalutamide administration. Toxicities that are in the opinion of the investigator(s) attributable exclusively to gemcitabine or cisplatin will not be considered DLT.

* 7 consecutive missed doses (out of 21 doses) of enzalutamide in 21 days due to study drug related toxicity.
* Missed day 8 dose of gemcitabine in cycle 1 will not be considered DLT.
* Delay of greater than 3 weeks from scheduled date in initiating cycle 2 due to study drug related toxicity.
* Discontinuation of a patient due to study drug related toxicity before completing cycle 1.

Dose Expansion. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Dose Expansion. PFS is defined as the time from randomization until objective tumor progression or death. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).

Dose Expansion. Overall survival is defined as the time from randomization until death from any cause, and is measured in the intent-to-treat population.

H. Lee Moffitt Cancer Center and Research Institute

Patient deaths listed in "all cause mortality" occurred after the Adverse Event reporting period, but within the Overall Survival follow-up period.

Dose Escalation: Level 1 dose of 80 mg enzalutamide (orally), with standard doses of cisplatin and gemcitabine via intravenous (IV).

Dose Escalation: Dose Level 1

Dose Escalation: Level 2 dose of 160 mg enzalutamide (orally), with standard doses of cisplatin and gemcitabine via intravenous (IV).

Dose Escalation: Level 2 Dose

Dose Expansion: Enzalutamide at MTD (160 mg) with standard doses of cisplatin and gemcitabine.

Dose Expansion

Dose Escalation: Level 1 Dose

Total

Age, Categorical

Age, Continuous

Sex: Female, Male

White Non-Hispanic

Black or African American

Asian

Hispanic or Latino

Other

Race/Ethnicity, Customized

United States

Region of Enrollment

This study did not meet the anticipated accrual goal of 24 participants.

Dr. Jingsong Zhang

Dose Escalation

Recommended Dose of Enzalutamide

Partial Response

Progressive Disease

Stable Disease

Complete Response

Not Evaluable

Dose Escalation - Level 2 dose of 160 mg enzalutamide (orally) with standard dose of cisplatin and gemcitabine via intravenous (IV).

All participants evaluable at time of analysis.

Overall Response Rate (ORR): Complete Response (CR) + Partial Response (PR)

Progression Free Survival (PFS)

Dose Escalation: Level 2 dose of 160 mg enzalutamide (orally) with standard dose of cisplatin and gemcitabine via intravenous (IV).

Overall Survival (OS)

Dose Escalation- Level 2 Dose

Enzalutamide at MTD (160 mg) with standard doses of cisplatin and gemcitabine.

Overall Study

Symptoms and General Pathology

Neoplasm Metastasis

Neoplastic Processes

Tin Fluorides

A single arm with patients with advanced cancer who have all of the following:

1. refractory pain and/or gait disturbance caused by pelvic bone metastasis, did not respond to conservative treatment.
2. osteolytic lesion (in predominance) suitable for the pain.
3. limited life expectancy (less than 3 years) or stopping medical treatment.

Exclusion criteria:

There are no absolute contraindications for the procedure; however, the relative contraindications are:

1. patients in poor condition with an expected survival period of less than 3 months.
2. patients with stable course, with long life expectancy (more than 3 years) or those considered candidates for major pelvic surgery including tumor removal and hip arthroplasty.
3. presence of bone destruction with soft tissue mass contaminating important organs, nerves and blood vessels (improvement is not expected).
4. Patients refusing to give a written consent to the study protocol.

Percutaneous image guided cementoplasty will be performed as follows:

Low-viscosity radiopaque bone cement will be quickly mixed and transferred to 1-ml syringes to reduce injection resistance. Injection will be initiated 2-4 min after mixing. When the resistance to cement injection becomes high in the beginning, the cement will be pushed in with a stylet, and it will go well afterward. As much bone cement as possible will be injected while avoiding leakage into the hip joint, sciatic notch, or veins under fluoroscopic monitoring. When significant cement leakage occurred at the initial stage, cement injection will be performed via another route or will be stopped and resumed when the cement viscosity increased. The cement will begin to harden after 8 min, and the operator, therefore, will aim to complete the delivery of the injection within 10 min. The injection needles must be removed before the cement hardens completely

Percutaneous cementoplasty

This study aimed to summarize the immediate operative and short-term efficacy and safety outcomes of percutaneous cementoplasty for pelvic metastases

Bone metastasis (BM) is the major cause of morbidity in patients with cancer. After lungs and liver, bone is the third most common site of metastatic disease. Prostate and breast cancers are responsible for the majority of bone metastases (up to 70%), followed by thyroid, lung, urinary bladder, and renal cancers, and finally melanoma. The incidence of bone metastasis is approximately 100,000 new cases per year in the united states and is increasing. Bone metastasis could result in skeletal-related events, including pain, pathological fracture, hypercalcemia, and nerve and visceral compression, which seriously affect the quality of life (QoL) of cancer patients. Bone metastases can be classified as osteolytic (osteoclast-mediated bone resorption), osteoblastic (osteoblast-mediated bone deposition), or mixed.

Fifty percent of the pain symptoms experienced by patients with cancer originate from BM. Tumor extension to neural structures, can cause a pain that may be radicular (exacerbated by percussion or palpation) and/or mechanical (exacerbated by movement). In advanced cases, pain can become intolerable and refractory to conventional therapies, resulting in walking disability, psychological and functional impact, and significant worsening of the QoL.

The effectiveness of surgery for bone metastasis in advanced cancer patients is limited to improvement of patients' quality of life. In most of these patients, complete resection or extended curettage of the bone metastasis with major reconstruction is often not feasible due to their poor general condition and accompanying other metastases. For some types of these bone metastases, surgical resection can lead to the stripping of the surrounding soft tissue and muscle attachment and addressing bone defects, causing more intraoperative bleeding, prolonged healing time, and increase the risk of wound complications, which in turn result in a longer recovery time for patients who usually have a limited life expectancy. Therefore, less invasive procedures, including percutaneous ablation (microwave ablation, radiofrequency ablation, cryoablation, and high-energy ultrasound) and/or bone cement \[polymethylmethacrylate (PMMA)\] injection, have become possible options. This is especially true for pelvic metastatic lesions because the surgery is particularly burdensome.

In addition, life expectancy of patients with metastatic bone disease is the most important factor in the decision making for surgical and/or medical treatment. A short life expectancy is in favor of the use of less invasive procedures, that have lower complication rates and shorter rehabilitation times. In these situations, interventional radiology procedures play an important either primary or complementary role in the management of bone metastases, especially in terms of palliation of pain, improvement of ambulation problems and treatment of fractures. This is because short life expectancies, more often, require palliative rather than curative regimens and make rapid pain relief to become a priority.

Aim of the study This study aimed to summarize the immediate operative and short-term efficacy and safety outcomes of percutaneous cementoplasty for pelvic metastases.

Materials and methods

Target Patients:

The study will include 20 patients with advanced cancer fulfilling the inclusion criteria and giving an informed consent to the study protocol (a single arm).

The following data will be collected from all patients:

1. Age at the time of the procedure
2. Gender
3. Primary cancer
4. Presence of lung metastasis
5. Presence of peritoneal metastasis
6. From the total bone scan:

   1. Unilateral or bilateral pelvic bone metastasis
   2. Solitary or oligometastasis (less than three sites) or multimetastasis ( 3 sites or more).
   3. Presence or absence of spine metastasis
   4. Presence or absence of lower limb metastasis
7. Previous surgery for cancer (site of the operation; pelviabdominal, lower limbs, spine, chest, brain)
8. Chemotherapy (preoperative, postoperative or both)
9. Radiotherapy (preoperative, postoperative or both)

Procedure:

The procedure will be performed under either spinal or general anesthesia. The patient will be placed in the lateral decubitus position with the surgical side up. The needle entry point will be adjusted with a fluoroscopic guide near the point 10 cm posterior to the anterior superior iliac spine. The skin and bone will be punctured by a 11-gauge needle. At least 2 or 3 different routes to the lesion will be established, and one needle will remain empty to allow decompression if possible.

The detailed procedure is described in the intervention section below. During the injection of PMMA, the anesthesiologist carefully will monitor the change in blood pressure and pulse rate, given the known toxicity of bone cement. The injected dose will vary according to the number of metastatic sites injected and their sizes.

All patients who has no contraindication to anticoagulation will be given (enoxaparin 40-60 mg per day) from 1 day before the procedure until ambulation was resumed for deep vein thrombosis prophylaxis.

The following procedural data will be collected:

1. Total cement amount
2. Injection needle number
3. Injection site number
4. Injected sites (Iliac bone or crest, acetabulum, ischium, pubic)
5. Duration of the procedure (in minutes)
6. Type of anesthesia used
7. If any other operation is performed concomitantly (nominate).

Outcome measures:

Primary outcome: is pain reduction:

Secondary outcomes: are

I- Gait function:

1. Gait status will be recorded pre and post operative
2. Gate function change II- Complications of the procedure (if more than one complication occurred in the same patient, all complications will be recorded)

A. Local:

1- Extraosseous bone leakage 2- Pathological fracture of the pelvic bones B. Systemic

1. Mortality
2. Pulmonary embolism
3. Bone cement implantation syndrome (BCIS):

Follow-up outcomes: at one month and 3 months

1. Mortality
2. Pain relapse (NRS score)
3. Gait relapse
4. Pathological fracture in the pelvic bones at the treated sites (by bone window CT).

Imaging Guided Cementoplasty for Pelvic Bone Metastasis

Immediate and Short-term Outcomes of Imaging Guided Percutaneous Cementoplasty for Pelvic Bone Metastases

To evaluate pain, the numerical pain score (NRS) will be used. The NRS is an 11-point numerical scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst possible pain (Figure 3) and pain is classified as mild pain if 1-4 points (tolerable), moderate if 5-6 points and severe if 7-10 points. NRS has been shown to be particularly reliable especially among patients with low health literacy. The NRS is also simple to score, and can be administered both orally and in written form.

Gait status will be recorded pre and post operative: with the following order from better to worse i. Normal ii. Limping iii. Independent with crutch or cane iv. Wheelchair v. Bed-ridden vi. Dead

It is a safety local outcome that reports extraosseous cement leakage (intra-articular "nominate joint", elsewhere)

A safety local outcome that is reported by history and confirmed by CT that could be impending or displaced

procedure related mortality is considered within 2 weeks of the procedure

(Pulmonary embolism caused by thrombus, fat, tumor emboli, or bone cement will be diagnosed by pulmonary CT with contrast if clinically suspected). For pulmonary embolism, clinical or radiological factors that might be related to its occurrence were collected, including primary cancer type, presence of lung metastasis, injected cement amount and number, local cement leakage during the procedure, pathologic fracture at the site for procedure, and injected route number.

1- defined as hypoxia, hypertension or both, and/or unexpected loss of consciousness occurring around the time of cementation. BCIS will be classified according to severity of symptoms:

1. grade 1 was moderate hypoxia (SpO2 \< 94%) or hypotension (fall in SBP \> 20%)
2. grade 2 was severe hypoxia (sPO2\<88%) or hypotension (fall in SBP\>40%) or unexpected loss of consciousness
3. grade 3 was cardiovascular collapse requiring cardiopulmonary resuscitation (CPR).

Assiut University

Resident Radiology

Infections

Digestive System Diseases

Heart and Blood Diseases

Skin and Connective Tissue Diseases

Gland and Hormone Related Diseases

Wounds and Injuries

Communicable Diseases

Intestinal Diseases

Aneurysm

Vascular Diseases

Kidney Calculi

Nephrolithiasis

Calculi

Leiomyoma

Aortic Aneurysm

Gastrointestinal Diseases

Myofibroma

Diverticulitis

Pregnancy, Ectopic

Pancreatitis

Intraabdominal Infections

Gallstones

Cholelithiasis

Cholecystolithiasis

Cysts

Ovarian Cysts

Polyps

Appendicitis

Cardiac Complexes, Premature

Abdominal Injuries

Pancreatic Diseases

Aortic Diseases

Gastroenteritis

Cecal Diseases

Neoplasms, Connective and Soft Tissue

Kidney Diseases

Urolithiasis

Urinary Calculi

Pathological Conditions, Anatomical

Diverticulum

Diverticular Diseases

Biliary Tract Diseases

Gallbladder Diseases

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Gonadal Disorders

Endocrine System Diseases

Subjects that present to the Emergency Department with complaints necessitating abdominal or pelvic imaging.

Duke employees that will voluntarily have an abdominal or pelvic ultrasound for with the sole purpose being for the study.

Joshua Broder, MD

Summary

1. Purpose and Objective: The purpose of this study is to test the feasibility of rapid acquisition of point of care 3D ultrasound in obtaining abdominal and/or pelvic images. The study will use a newly developed acquisition method and post-processing technique to create three dimensional image models of the abdomen and/or pelvis.
2. Study activities and population group. The study population will be a convenience sample of patients of any age presenting to the Emergency Department with complaints necessitating a clinical abdominal and/or pelvic imaging. The study intervention includes acquisition of research ultrasound images, which will not be used for clinical care, and comparison of these images with clinically obtained images. Other clinical data such as surgical and pathology reports will also be reviewed. 3.Data analysis and risk/safety issues. This is a pilot study intended to determine feasibility and to refine image reconstruction algorithms. Research images will be compared to clinical images. Comparison of research images with final diagnosis will also occur. The research intervention, an ultrasound exam, has no known safety risks. The only risk to subjects is loss of confidentiality.

This study is observational, not interventional, because the experimental ultrasound will be performed in all subjects and will not be used in the clinical care of patients (consequently, will not have the opportunity to affect clinical outcomes). Experimental images will be reviewed after completion of clinical care and will not be provided to the clinicians caring for the subjects. The investigators are not measuring the effect of the ultrasound examination on the subjects' outcomes.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of Radiation With Sorafenib in Advanced Cancer	NCT00610246	Cancer	Sorafenib	18 Years -	University Health Network, Toronto
Cost-effectiveness Evaluation of the Use of a Patient Specific Instrument for Surgical Resection of Malignant Bone Tumor Within the Pelvis Versus the Conventional Surgical Treatment	NCT02544711	Sarcoma, Bone T...	Patient specifi... Conventional su...	18 Years -	Nantes University Hospital
Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer	NCT02300610	Bladder Cancer Carcinoma, Tran... Renal Pelvis Ca... Ureter Cancer Urethra Cancer	Enzalutamide Cisplatin Gemcitabine	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
A Study of Radiation With Sorafenib in Advanced Cancer	NCT00610246	Cancer	Sorafenib	18 Years -	University Health Network, Toronto
A Study of Radiation With Sorafenib in Advanced Cancer	NCT00610246	Cancer	Sorafenib	18 Years -	University Health Network, Toronto
Imaging Guided Cementoplasty for Pelvic Bone Metastasis	NCT06231628	Imaging Guided Percutaneous Ce... Pelvic Bone Met...	Percutaneous ce...	-	Assiut University
Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer	NCT02300610	Bladder Cancer Carcinoma, Tran... Renal Pelvis Ca... Ureter Cancer Urethra Cancer	Enzalutamide Cisplatin Gemcitabine	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Imaging Guided Cementoplasty for Pelvic Bone Metastasis	NCT06231628	Imaging Guided Percutaneous Ce... Pelvic Bone Met...	Percutaneous ce...	-	Assiut University
Point of Care 3D Ultrasound for Various Applications: A Pilot Study	NCT02831556	Appendicitis Evidence of Cho... Gallstones Pregnancy, Ecto... Aortic Aneurysm Kidney Stones Intrauterine Pr... Diverticulitis Abdominal Injur... Tumors Pancreatitis Digestive Syste... Gastrointestina... Intraabdominal ... Intestinal Dise... Pregnancy Vascular Diseas... Uterine Fibroid... Ovarian Cysts Uterine Abnomin... Bladder Abnomin... Testicular Abno... Polyps		-	Duke University
Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum	NCT03360760	Osteosarcoma of...	Doxorubicin Cisplatin Methotrexate Ifosfamide definitive surg... pre surgical ch...	10 Years - 40 Years	Peking University People's Hospital

Spots Global Cancer Trial Database for pelvis

Every month we try and update this database with for pelvis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for pelvis

Every month we try and update this database with for pelvis cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for pelvis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.